TABLE 4.

Analysis of relapse stratified by molecular subtypes and genetic alterations.

		Relapse		p-value
		No; n = 27	Yes; n = 5
Follow-up time median (IQR)		31 (25–35)	34 (16–50)	0.70 a
Molecular subtype b				0.24 c
	Genetic alteration(s)
Hyperdiploid	ABHD17B::CEMIP2 d	1 (3.7%)	0 (0.0%)
	CSF3R p.G147R + DBF4B::EFTUD2 d	1 (3.7%)	0 (0.0%)
	FLT3 p.N676K	1 (3.7%)	0 (0.0%)
	FLT3 p.D835E + R833-D834_Ins:S	1 (3.7%)	0 (0.0%)
	Hyperdiploid	6 (22.2%)	0 (0.0%)
	NRAS p.G12D + PAX5 p.R38C	1 (3.7%)	0 (0.0%)
	NF1 p.R1306* + CREBBP p.G1542V	0 (0.0%)	1 (20.0%)
	DUX4 e + TP53 p.R267P + IKZF1 p.D186Y	0 (0.0%)	1 (20.0%)
	total	11 (40.7%)	2 (40.0%)
ETV6::RUNX1	ETV6::RUNX1	2 (7.4%)	0 (0.0%)
	ETV6::RUNX1 + ATM p.P604S	1 (3.7%)	0 (0.0%)
	total	3 (11.1%)	0 (0.0%)
ETV6::RUNX1-like	NSD2 p.E1099K	0 (0.0%)	1 (20.0%)
	TCF3:FLI1 + SCAF8::FER1L4 d	1 (3.7%)	0 (0.0%)
	total	1 (3.7%)	1 (20.0%)
Ph-like	KRAS p.Q61P	1 (3.7%)	0 (0.0%)
	Ph-like	1 (3.7%)	0 (0.0%)
	P2RY8::CRLF2	1 (3.7%)	0 (0.0%)
	total	3 (11.1%)	0 (0.0%)
PAX5alt	NRAS p.G12S + PAX5 p.P34L	0 (0.0%)	1 (20.0%)
	PAX5::ETV6	1 (3.7%)	0 (0.0%)
	total	1 (3.7%)	1 (20.0%)
DUX4	DUX4	1 (3.7%)	0 (0.0%)
	DUX4::IGH + PTPN11 p.D61Y + TP53 p.P152L + ZEB2 p.H1038R	1 (3.7%)	0 (0.0%)
	DUX4 p.I65N + ETV6_Q12del	1 (3.7%)	0 (0.0%)
	ERG::LINC01423	1 (3.7%)	0 (0.0%)
	total	4 (14.8%)	0 (0.0%)
MEF2D	MEF2D::BCL9 + ATM p.P604S	0 (0.0%)	1 (20.0%)
TCF3::PBX1	TCF3::PBX1 + TCF3_S338fs*10	1 (3.7%)	0 (0.0%)
ZNF384	EP300::ZNF384	1 (3.7%)	0 (0.0%)
B-other	Unclassified	2 (7.4%)	0 (0.0%)

^a Wilcoxon rank sum test.

^b Final classification.

^c Fisher’s exact test (by molecular subtype).

^e Classified as DUX4/Hyperdiploid.

^d Novel fusion transcripts.

In bold are depicted the high-risk alterations identified in patients initially classified as intermediate-risk according to the protocol guidelines.